Clinical Trial: Pharmacologically Triggered Migraine Without Aura and Neuroimaging

Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional

Official Title:

Brief Summary:

Migraine is a highly disabling disorder affecting 14% of the general population Worldwide and ranked as the 6th most debilitating disease worldwide by the WHO. One of the most fundamental questions of migraine, which remains to be elucidated, is the mechanism behind the generation of migraine attacks.

We will use calcitonin gene-related peptide (CGRP) and sildenafil as pharmacological triggers of migraine, combined with advanced neuroimaging techniques, to investigate the attack initiating pathophysiology.

Both substances have previously been administered to healthy participants and migraine without aura patients, inducing headache and migraine-like-attacks.

We hope to contribute with novelty to the current understanding of the migraine pathophysiology and development of more efficient treatment of migraine.

Detailed Summary:
Sponsor: Danish Headache Center

Current Primary Outcome: CGRP and sildenafil induced MRI-changes [ Time Frame: 0-6h ]

Original Primary Outcome: Same as current

Current Secondary Outcome:

Original Secondary Outcome:

Information By: Danish Headache Center

Dates:
Date Received: May 4, 2017
Date Started: August 2016
Date Completion: December 2018
Last Updated: May 4, 2017
Last Verified: May 2017